Top Tech Companies (719)
Don't see your company?
Create a company profile
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in clinical and commercial manufacturing production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking, and support services from its Oklahoma City state-of-the-art facilities.
Promentis Pharmaceuticals focuses on developing antipsychotic drugs to treat schizophrenia.
Escient Pharmaceuticals is a privately held biotechnology company.
PLx Pharma develops and commercializes non-steroidal anti-inflammatory drugs for prescription and over-the-counter markets.
Dompé is an Italian bio-pharmaceutical company that focuses on innovation, where a long tradition in the field of personal wellness goes hand in hand with a commitment to research and development to meet hitherto unsatisfied therapeutic needs. Established in 1940 in Milan, Dompé continues to have its headquarters in this city. In Italy, it also has offices in L’Aquila, with an industrial and biotech research hub, and in Naples, where the Company has an R&D division. Dompé also has branches in the United States (Boston and San Francisco), in Albania (Tirana) and China (Shanghai). Primary Care Dompé, with its products offered at over 10,000 pharmacies in Italy, is engaged in the development and distribution of ethical drugs and self-medication, adjuvants, medical devices and cosmetics, and in the fields of vitamin and mineral supplements and personal hygiene. The therapeutic areas include cardiovascular, gastrointestinal, paediatrics, neurology, urology, ophthalmic, stomatology and respiratory. Dompé currently markets 50 million medication packages in roughly 40 countries around the world. Biotech and rare diseases The Biotech unit is a manifestation of Dompé commitment to meeting unsatisfied patient needs all around the world. The Biotech Unit focuses specifically on the rare diseases field, such as ophthalmology, for instance, an area in which the company has developed and marketed the first ophthalmic product based on rhNGF (the molecule discovered by Nobel Prize winner Rita Levi Montalcini) for patients suffering from neurotrophic keratitis. For more information on Dompé visit www.dompe.com To explore career opportunities at Dompé visit http://www.dompe.com/Careers-en/
We see things from the patients' perspective and believe what comes before and after a drug is just as important as the drug itself. We go #BeyondBiology
Our mission is to accelerate access to medicines for patients in every corner of the globe: Clinical Services, Product Access and Commercialisation, Pharmacovigilance and Regulatory Affairs
Biologit specialises in active safety surveillance solutions for the life sciences, including human and veterinary pharmacovigilance, cosmetovigilance, nutrivigilance and materiovigilance. Biologit MLM-AI is a comprehensive platform designed to monitor the scientific literature for adverse events and new risks related to products from clinical development to post-market. Built for teams of all sizes, its flexible workflow, global and local unified scientific database and unique AI enabled screening and productivity features deliver fast and fully traceable results for any safety surveillance screening requirements. Biologit offers a complete portfolio of services, including Qualified Person for Pharmacovigilance (QPPV) and and Responsible Person for Pharmacovigilance (RPPV) in Clinical Trials
Biscayne Pharmaceuticals discovers and develops novel therapies based on growth hormone-releasing hormone (GHRH) analogs.
Cisplatin and other platinum compounds are essential chemotherapeutic components for many pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity in many patients, leaving many survivors of childhood cancer with permanent and irreversible hearing loss. Permanent hearing loss, even minimal, acquired at a young age has a devastating impact on development, education, and socialization and a lifelong negative impact on Quality of Life. There are no currently approved treatments for the prevention of platinum-induced hearing loss. At Fennec Pharmaceuticals, we are dedicated to the development of our investigational agent, PEDMARK™, for the prevention of ototoxicity in children, and we hope that this will enable more children to retain their hearing. In honor of our namesake, the fennec fox, we strive to embody adaptability and resourcefulness in everything we do. Please see www.fennecpharma.com for more information.
.jpeg)
.png)
ASCP is the only international professional society devoted to optimal medication management and improved health outcomes for all older persons. Founded in 1969, ASCP is a non-profit membership organization currently based in Alexandria, VA. ASCP represents over 9,000 pharmacy professionals, including students, serving the unique medication needs of the senior population. Our members range in the services they provide and serve seniors in a variety of settings.
Oscine Therapeutics is a new biotechnology company based on discoveries made and developed at the University of Rochester Medical Center
With 25,000+ products, niche-focused reps, and the “in your door in twenty-four” promise, Dealmed is the leader along the eastern seaboard in medical & pharmaceutical supply distribution, providing better products at better prices faster so you can deliver better care. We help our customers re-imagine their supply chain by: ☑ Knowing when, how, what, and where you need your supplies through inventory monitoring and predictive replenishment ☑ Reducing costs throughout the supply chain through strategic hubs, aggressive pricing, integrated ordering, and other initiatives ☑ Understanding what product works best for which procedures ☑ Standardization across settings and locations ☑ Shipping 5,000+ orders per day in multiple units of measure WHAT MAKES DEALMED DIFFERENT? With an emphasis on domestically sourced products and sophisticated technology that integrates with clients’ PO systems, Dealmed gives you an edge to a better and healthier supply-chain. Combined with end-to-end solutions for warehousing, inventory, and distribution, our third-party logistics program is as seamless as any first-party operation. ☑ Exclusive Access: Leading Brands, Originals & Alternatives ☑ Rapid Access: Exclusive Contracts, GPOs & Tiered Pricing ☑ Priority Access: Manufacturers’ Backorders & Hard-to-Get Products CUSTOMERS Hospitals & Healthcare Systems | Physician Offices | Ambulatory Surgery Centers | Urgent & Community Health Care Centers | Dialysis Centers | EMS & First Responders | Government Agencies | Consumer & Specialty Markets SERVICES Medical Supply Distribution | Medical Equipment | Pharmaceuticals & Vaccines | Surgical Supplies & Equipment | Specialty Market Distribution | 3PL Services How can Dealmed help your business run profitably and stay ahead of whatever comes next? It starts by reimagining your supply chain. Contact a Dealmed sales rep: www.dealmed.com/register
NextSource Biotechnology is a biotechnology and pharmaceutical company located in Miami.
Aesthetics technology firm that develops and globally commercializes novel cosmetic products
Andelyn Biosciences is a biopharmaceutical CDMO Pioneering Solutions That Turn Hope into Reality™. Capabilities span viral vector and vaccine process and analytical development, small to large scale adherent and suspension based GMP drug substance manufacturing up to 2000L, and finished drug product manufacturing services located in Columbus, OH USA. Having 20+ years of experience with viral vector and vaccine manufacturing, Andelyn offers its clients direct access to globally recognized thought leaders with troubleshooting / characterization expertise and GMP material produced for over 75+ worldwide clinical trials. In addition to producing over 400+ cGMP clinical batches and 2000+ research-grade productions, Andelyn currently provides research and tox grade plasmids with an additional offering of GMP plasmid manufacturing (early 2022), advanced quality systems, full regulatory support, semi-automated to automated fill stations, and supply chain vertical integration. Its state-of-the-art 185,000 sq ft clinical and commercial manufacturing facility comprises 14+ upstream production suites for customization of new programs and tech transferred programs. Andelyn offers clinical through commercial-scale capabilities that will help accelerate the development and manufacturing of innovative therapies to bring more treatments to more patients
MSDx is a personalized medicine company developing blood testing products for brain diseases.
.jpeg)
PDMI is growing! If you'd like to join our team, view our open positions at https://www.pdmi.com/careers. At PDMI, our flexibility, service and independence ensure that we are a PBM service partner that's anything but cookie cutter. For 35 years, we've provided pharmacy claims adjudication services and a suite of pharmacy benefit administrative services that help our clients meet their business objectives. Our 340B Contract Pharmacy Solution was designed around regulatory compliance, providing comprehensive reporting, and timely inventory replenishment. Here are a few reasons why we’re unique, like you: • Flexible. PDMI provides comprehensive pharmacy benefit services. You have the flexibility to choose the PDMI services that fit your business model. • Great Service. Our people are empowered to take action to ensure timely responsive service. • Our Independence. PDMI is a privately held company. We work for our clients – not shareholders.
CONTINUUS’ mission is to produce high-quality drugs that can be delivered to patients more effectively and at a lower cost. In achieving this goal, we look to radically transform the pharmaceutical manufacturing industry, steering it away from outdated batch systems to state-of-the-art continuous processes. CONTINUUS is leveraging a novel continuous manufacturing platform called Integrated Continuous Manufacturing (ICM), initially developed through an $85 M joint research project between Novartis and MIT. With ICM, we will improve affordability and accessibility of pharmaceuticals on a global scale. Our work is critical because the current manufacturing systems are time- and cost-inefficient, and are beset with quality problems. It is not unusual for manufacturing lead times, from start to finish, to be over one year, and studies have shown that the industry loses over $50 B annually due to wasteful processes. More importantly, these problems impact patient care. Hundreds of drugs are placed on the US FDA drug shortage website, many of which are life-saving (e.g., oncology drugs). To solve these problems, we offer a number of solutions: In addition, CONTINUUS is currently collaborating with hospital systems and pharmacy chains to establish its own generic business, where high-quality, low-cost drugs will be manufactured in the United States. To achieve our goals, CONTINUUS has assembled a team of talented engineers and scientists, with skills ranging from analytical chemistry to drug formulation. Rather than producing medicines through batch-wise, step-by-step processes, ICM allows for fully continuous and automated operations, where the synthesis of the active ingredient and the final dosage form are integrated into a seamless process. This novel method will allow “on-demand” manufacturing of pharmaceuticals, improving affordability and accessibility of pharmaceuticals on a global scale.
A pharmaceutical company focused on developing innovative chemistry to detect diseases that involve the presence of amyloid proteins.
